TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05092984
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 77 patients will be treated with spironolactone Mylan 25mg/day for the first 3 months of the study. Dosage adjustment can be performed according to the eGFR (estimated Glomerular Filtration Rate) concentration at baseline and the serum potassium variation.~During the last 3 months of the study, all the patients will be treated with spironolactone Mylan 25mg. Dosage adjustment can be performed according to the serum potassium variation.
Study: NCT05345509
Drug: IVL3003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil Long-Acting Injection, once S.C Injection
Study: NCT05345509
Drug: IVL3003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil Long-Acting Injection, once IM Injection
Study: NCT05943015
Drug: Patient controlled intravenous analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afterward of the operation, patients will be treated with patient-controlled analgesia with intravenous tramadol, with 20 mg bolus 20 minutes lock time, 4-hour limit 100 mg and 24-hour limit 400 mg
Study: NCT05024799
Drug: Fentanyl, propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients in this group will be administered with fentanyl and propofol
Study: NCT05024799
Drug: fentanyl and dexmedetomindine
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patients in this group will be administered with fentanyl and dexmedetomindine
Study: NCT05560477
Drug: AM3101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable drug product.
Study: NCT05560477
Drug: Saline Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL 0.9% normal saline
Study: NCT00000961
Drug: Anti-HIV Immune Serum Globulin (Human)
Normalized name: immune globulin subcutaneous (human)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04858711
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the fentanyl group, patients will be administered 2 mcg/kg fentanyl in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of normal saline solution 0.9%. As maintenance, they will be receiving 1mL/10kg/h of normal saline solution 0.9%.
Study: NCT05093335
Drug: [68Ga]-Pentixafor
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intravenous bolus of 3 -5 mCi of \[68Ga\]-Pentixafor will be injected in all participants.
Study: NCT05161468
Drug: Corticosteroid Injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of triamcinolone acetonide (40 mg/ml) will be drawn with 1 ml normal saline into a 3 ml syringe and labeled. It will then be delivered into the AC joint per standard injection procedures (estimated 1-2 ml).
Study: NCT04930809
Drug: VER-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: standardised cannabis extract (containing 21 mg THC per gram drug product)
Study: NCT00241995
Drug: Anticonvulsants
Normalized name: ANTICONVULSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06485219
Drug: 11.2 mg/m2 Purinostat Mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puesta Mesylate for Injection: Intravenous infusion, Phase IIa is administered on Days 1, 4, 8, and 11 of each cycle, with 3 weeks (21 days) as a single dosing cycle.
Study: NCT06485219
Drug: 15 mg/m2 Purinostat Mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puesta Mesylate for Injection: Intravenous infusion, Phase IIa is administered on Days 1, 4, 8, and 11 of each cycle, with 3 weeks (21 days) as a single dosing cycle.
Study: NCT04393207
Drug: Dexamethasone and methylprednisolone (CG)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transverse abdominis plane block will be performed and the neurofascial plane between the internal oblique and the transverse abdominis will be infiltrated with with bupivacaine alone.
Study: NCT04393207
Drug: Control group (Bupivacaine)- (BPG)
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transverse abdominis plane block will be performed with plain bupivacaine
Study: NCT05009992
Drug: ONC201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally (PO)
Study: NCT06043713
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Receive IV
Study: NCT04827992
Drug: Medical Marijuana
Normalized name: Picea mariana resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group can choose what type, how much, and when to use medical marijuana to use.
Study: NCT06553157
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins are drugs known to help lower total cholesterol and reduce the risk of a heart attack or stroke. Statins include atorvastatin , fluvastatin , lovastatin , pitavastatin , pravastatin, rosuvastatin and simvastatin.
Study: NCT05039190
Drug: HBM9161 Injection (680mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBM9161 Injection
Study: NCT05039190
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Injection
Study: NCT06109467
Drug: 5-Fluorouracil + leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive 400 mg/m\^2 5-Fluorouracil (5FU)+ 400 mg/m\^2 leucovorin day 1 of each 2 week cycle; 5FU continuous infusions on days 1 and 2 of each 2 week cycle. (5FU + leucovorin may be eliminated from regimen per PI discretion)
Study: NCT05488548
Drug: EP31670
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP31670 (also known as NEO2734) is a first-in-class dual BET and CBP/p300 inhibitor.
Study: NCT05376566
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline in a volume corresponding to dead space (0.3-1.8 ml) will be instilled and aspirated 10 min later; the instillation is completed 3 times.
Study: NCT05321069
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05818553
Drug: PRAX-562
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral or G-tube treatment.
Study: NCT06235983
Drug: LY3537982
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05147467
Drug: APG2575
Approvals — FDA: no, EMA: no, PMDA: no
Description: APG-2575 orally once daily at 600mg dose levels, every 28 days as a cycle.
Study: NCT06456528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04401423
Drug: TXA127
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg per day
Study: NCT05834231
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT05552781
Drug: H002 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small molecule, Capsule
Study: NCT04401423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg per day
Study: NCT05954286
Drug: Placebo (PO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsules
Study: NCT05529056
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ophthalmic solution
Study: NCT04098666
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet identical to metformin, up to 4 tablets a day
Study: NCT04677673
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified SOX Chemotherapy regimen A cycle consists of Day 1: Oxaliplatin 100mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 60mg/M2 oral (twice daily) Repeated every 22nd day
Study: NCT05162027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once every 4 weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.
Study: NCT06061536
Drug: Lipovirtide 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipovirtide 10mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）；
Study: NCT06061536
Drug: Lipovirtide 40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipovirtide 40mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）；
Study: NCT06061536
Drug: Lipovirtide 60mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipovirtide 60mg+3TC+TDF（LP-80：once every 2 weeks；3TC+TDF：once daily）；
Study: NCT05199662
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching IV TNK
Study: NCT06374667
Drug: Y-3 intravenous injection
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients included will be given Y-3 intravenous injection for 7 consecutive days.
Study: NCT06573970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pill appears like real atomoxetine pill but has no therapeutic ingredient and benefit. The same schedule to distribution as Atomoxetine arm.
Study: NCT05875519
Drug: Local anaesthesia with vasocontrictor (Mepivacaine hydrochloride 20 mg (2%) + Levonordefrin hydrochloride 0.06 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine hydrochloride 20 mg (2%) + Levonordefrin hydrochloride 0.06 mg
Study: NCT06208384
Drug: Statin eye drop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of topical atorvastatin eye 8 times a day; in addition to eyelid hygiene and artificial tear drops (8 weeks)
Study: NCT06208384
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of topical eye drops as a placebo same as intervention group but without active ingredient of atorvastatin 8 times a day; in addition to eyelid hygiene and artificial tear drops (8 weeks)
Study: NCT04964947
Drug: Tobramycin Injection
Normalized name: tobramycin Injection
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 80 milligrams of tobramycin diluted in 40 milliliters of normal saline
Study: NCT06422884
Drug: ENV-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet, dosed once a day
Study: NCT04520139
Drug: N-Acetyl-Cysteine
Normalized name: Dendrimer N-acetyl-cysteine
DrugBank: Acetylcysteine zidrimer (DB16496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05046639
Drug: 10 mL preservative free saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL preservative free saline.~Crossover treatment 5 days later using Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL 2% lidocaine.
Study: NCT05140512
Drug: ZOLADEX® 3.6 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZOLADEX® was administered as 3 Subcutaneous (SC) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
Study: NCT05576038
Drug: Freedom SimpleCap Powder
Normalized name: Freedom SimpleCap Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freedom SimpleCap Powder is a high functionality capsule and tablet excipient composite comprised of filler, glidant, disintegrant and lubricant (ingredients include: Microcrystalline Cellulose, Silicon Dioxide Colloidal, Sodium Starch Glycolate, Sodium Stearyl Fumarate). This capsule is dye, lactose and gluten free and will not interfere with the AhR pathway. Freedom SimpleCap Powder makes oral capsule formulation convenient, quick and simple Thus, this SimpleCap Powder will be an appropriate placebo comparator for this study.
Study: NCT04669496
Drug: Neoadjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD1 antibody (Toripalimab) combined with GEMOX chemotherapy and Lenvatinib neoadjuvant treatment
Study: NCT05537051
Drug: PM1021, PM8001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered with PM1021 on Part A Day 1. Participants will be administered with PM1021 and PM8001 on Part B Day 1. PM1021 and PM8001 combination therapy administrated every 3 weeks from Part C Day 1 until disease progression, intolerable toxicity, until the patient withdraws/is withdrawn, or study completion.
Study: NCT06014749
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: local anesthetic
Study: NCT05656105
Drug: DPA-714 PET/MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPA-714 PET/MRI
Study: NCT06443502
Drug: Concomitant Antibiotic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin, metronidazole, vancomycin, amoxicillin clavulanate or rifaximin.
Study: NCT06264414
Drug: DTT106
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral route
Study: NCT06247657
Drug: BL0006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be administered BL0006 via intravenous infusion at the corresponding dose level on days 1 and 8 of a 21-days treatment cycle.
Study: NCT06275763
Drug: Phase C: Eplerenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomly assigned to this arm take Eplerenone and placebos of Spironolactone and Torasemide
Study: NCT06275763
Drug: Phase C: Spironolactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomly assigned to this arm take Spironolactone and placebos of Eplerenone and Torasemide
Study: NCT06275763
Drug: Phase B: Triplixam / Elestar HCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replacement of ineffective antihypertensive treatment based on 3 or more antihypertensive drugs (single or dual drug preparations) with a triple single pill combination (SPC) based on optimally combined antihypertensive drugs: perindopril + indapamide + amlodipine (P+I+A) or olmesartan + hydrocholothiazide + amlodipine (O+H+A).
Study: NCT05445843
Drug: JDQ443
Approvals — FDA: no, EMA: no, PMDA: no
Description: JDQ443 orally administered
Study: NCT06153602
Drug: Acetaminophen 500Mg Tab
Normalized name: ACETAMINOPHEN 500MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tab oral prn for postoperative pain score 1-3 q 6 h
Study: NCT05070260
Drug: Intravenous Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
Study: NCT05400122
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis. It is a cell cycle phase nonspecific agent. Cyclophosphamide also possesses potent immunosuppressive activity.
Study: NCT02006173
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00106548
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-25mg/week
Study: NCT05658016
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TK112690 Placebo treatment Pre \& Post Radiation
Study: NCT06051240
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: White round tablet, 10 mm. Identical to experimental drug (lithium)
Study: NCT06466538
Drug: Calcium hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: intracanal medicament
Study: NCT06466538
Drug: Leddermix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leddermix
Study: NCT06466538
Drug: Boswellia
Normalized name: boswellia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boswellia
Study: NCT04944654
Drug: BIKTARVY 50Mg-200Mg-25Mg Tablet
Normalized name: Biktarvy 50mg-200mg-25mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination single tablet anti-retroviral therapy: bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg
Study: NCT05161611
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg of oral zinc sulfate will be given to neonates per day
Study: NCT05970185
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of polyethylene glycolized recombinant human granulocyte-stimulating factor injection 6mg bid in the experimental group the day after the end of chemotherapy
Study: NCT06159387
Drug: Cannabis Extract Oil SR Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: After randomization, in a double blind model, subjects receive cannabis extract or placebo conditioned in identical vials with the same volume of substance.~Everyone will undergo psychotherapy in the CBT (cognitive behavioral therapy) model
Study: NCT05529849
Drug: TCMCB07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of TCMCB07
Study: NCT05529849
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching subcutaneous placebo
Study: NCT06198803
Drug: L Carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study population will be randomly divided into 2 groups, 1 group will receive Carnitine supplementation in a dose of 100mg/kg/day
Study: NCT06346184
Drug: RLD2302
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 1 tablet once per period
Study: NCT06346184
Drug: RLD2102
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 1 tablet once per period
Study: NCT05862701
Drug: Sulphur
Normalized name: Sulphur
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% Sulfur ointment
Study: NCT05592912
Drug: HydroLenz Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: The HydroLenz injection will be administered at the conclusion of the vitrectomy procedure on the operative day
Study: NCT03932656
Drug: Psychopharmaceuticals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy will be implemented according to the National Institute for Health and Care Excellence guidelines and will target comorbidities if present to such extent that warrants a pharmacological intervention. If not needed, patients will not use medication. Most patients will be recommended to hospitalization by their outpatient psychiatrists who prescribe the medication. If needed, medication will be changed to meet the guideline standards (i.e., tapering off benzodiazepines or augmentation with a mood stabilizer). The medication will be controlled but not directed by the study.
Study: NCT05584670
Drug: SAR445877
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrate for solution for infusion
Study: NCT05063500
Drug: polyene phosphatidylcholine capsules, 228mg/ particle.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: each oral polyene phosphatidylcholine 456mg, three times daily for 4 weeks.
Study: NCT05726851
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2025 matched placebo IV infusion.
Study: NCT05405868
Drug: Nicotinomide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinamide tablets (750mg)
Study: NCT05405868
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT06185829
Drug: Neurloeptanalgesic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual neuroleptanalgesic treatment
Study: NCT04973982
Drug: Adoport
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 month treatment, given twice daily, oral tablet. Dose titrated according to levels target 6-10ng/ml
Study: NCT05741437
Drug: CKD-378, QD, PO Drug: D745, D150, QD, PO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durg: CKD-378, QD, PO Drug: D745, D150, QD, PO
Study: NCT04898920
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will receive 10 ml of normal saline as a placebo dexamethasone before surgery.
Study: NCT03988231
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to enoxaparin 40mg once daily versus saline placebo at 8 hours after surgery and continued for the duration of inpatient stay.
Study: NCT04911881
Drug: IBI321
Approvals — FDA: no, EMA: no, PMDA: no
Description: Several dose levels will be evaluated for IBI321 administered as a single agent. IBI321 will be given via IV infusion on Day 1 of each cycle until disease progression or loss of clinical benefit.
Study: NCT05223660
Drug: Low dose Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 4 capsules, followed by multiple doses on Days 8-12
Study: NCT05223660
Drug: High dose Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 6 capsules, followed by multiple doses on Days 8-12
Study: NCT05916781
Drug: Glucocorticoid
Normalized name: Glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in steroid tapering group will stop taking glucocorticoid after the first 6 months.~Participants in steroid maintenance group will consistently take glucocorticoid for 18 months, and stop the use of glucocorticoid after 18 months if they do not flare.
Study: NCT05381142
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered the same as Elinzanetant (BAY3427080)
Study: NCT06213844
Drug: IBI3002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of IBI3002 (Dosage 1, Dosage 2, Dosage 3, Dosage 4, Dosage 5, Dosage 6), administered subcutaneously on Day 1
Study: NCT06213844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Placebo, administered subcutaneously on Day 1
Study: NCT06372561
Drug: Melatonin (dressing material)
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: melatonin powder 250mg (sigma, Aldrich)- white powder mixing with saline and applied on dental pulp
Study: NCT06387186
Drug: Leucine-Enriched Essential Amino Acid powder
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucine-Enriched Essential Amino Acid Powder will be orally/enterally administered by mixing in water or ketogenic formula.
Study: NCT05561361
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aldosterone receptor antagonists are recommended by guidelines for the treatment of bilateral primary aldosteronism.
Study: NCT05594472
Drug: Topical garamycin cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional topical treatment will be applied for 5 consecutive days on a comparable erosion
Study: NCT00082251
Drug: Niacin extended release and simvastatin tablets
Normalized name: niacin / simvastatin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06218680
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: recieve propofol 0.5 mg/kg intravenously at end of sevoflurane anesthesia
Study: NCT05803200
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention was given as this is an observational study.
Study: NCT06222671
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous (SC) injection.
Study: NCT06026748
Drug: XJ103 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: XJ103 is a humanized monoclonal antibody.
Study: NCT06026748
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contains only excipients.